You are a very unwise individual if you plan on staying on here. I feel bad for your family if you are the bread winner.
Teva is going down just a matter of time. Go ahead and stick around and let me know how that works out for you.
To compare the state Teva is in now with the whole industry is a joke! No other pharma company is close to being in the state that Teva finds itself in.
Teva is
planning to cut about 10,000 employees in both the U.S. and Israel. That is a massive amount of people to be laying off. When you think about it in more detail, these layoffs will do nothing but hurt the company even more at a time when it is already fragile. Sure, cutting that many employees will greatly reduce operating expenses associated with the company. The problem is that cutting that many employees means a smaller sales force to push the current products for improved sales. In my opinion, it is counterproductive to eliminate that many employees. What I also don't like about this is that Teva won't just cut low level employees. They are planning to cut top level executives as well. According to a financial news website Calcalist, Teva plans to even remove its Chief Scientific Officer and President of Research and Development Michael Hayden. In my opinion, cutting the Chief Scientific Officer at a time like this is like the company wants to shoot itself in the foot. The reason why I believe that is because Teva's problem is not the employees or the executives that it employs. The problem with Teva is its business model. It needs to steer away from being a generics driven company, and head back to R&D development of new drug compounds. What I mean by that is developing new drug compounds like Copaxone way back when. In other words, develop non-generic drugs like all the other big pharma companies do such as Merck (
MRK), Pfizer (
PFE), Eli Lilly (
LLY), GlaxoSmithKline (
GSK), Novartis (
NVS) and several others. All these big pharma companies do have some generic drugs, but they don't rely on them as their primary form of business. They focus on R&D of new drug compounds that are non-generic. That's what Teva needs to do to become successful. This move of laying off employees and cost cutting is only delaying the inevitable in my opinion.